AstraZeneca to reissue vaccine data "within 48 hours" after questions raised

AstraZeneca manufacturing employee

AstraZeneca manufacturing employee

Magic Mountain has nothing on the ups and downs of AstraZeneca's COVID-19 vaccine.

Science's COVID-19 reporting is supported by the Heising-Simons Foundation.

"The bottom line is: that doesn't change recommendations on the AstraZeneca vaccine at this time".

On Monday, AstraZeneca published a news release saying its new Phase 3 clinical trial data showed its two-dose vaccine was 79 per cent effective at preventing symptomatic cases of COVID - a significant improvement over the 62 per cent efficacy the company reported in November.

Two-thirds of the volunteers in the trial received an initial standard dose of the vaccine followed by a booster dose 4 weeks later; the other one-third received placebo shots.

Anand has said Canada is expected to receive a total of 9.5 million doses of COVID-19 vaccines by the end of the first quarter of this year.

"The message is that the efficacy and the safety of the vaccine have been shown", senior Health Canada official Marc Berthiaume told reporters.

The DSMB is a group of outside experts who monitor the study. She notes the trial was not created to answer the question of how well the vaccine prevents severe disease. "Encouraging people to think they have flawless protection from serious harm if they are vaccinated is a terribly risky message". The United States has said it is sharing 1.5 million doses of the AstraZeneca vaccine with Canada as early as this week.

Canada expecting surge in COVID-19 vaccine deliveries to begin this week
It was 100% effective in preventing hospitalisation and death due to the virus. A total of 539,408 doses have been administered as of Monday.

The US results come at a time when there is concern over instances of blood clots among some European beneficiaries vaccinated with the AstraZeneca shot. "There was no concern as to the safety of the vaccine".

After briefly halting its use, many European countries have resumed using it in their inoculation programmes after a regional regulator said it was safe, while several country leaders are also taking the vaccine to boost confidence. That finding does not rule out, however, that such a side effect could still occur in rare instances.

The AstraZeneca vaccine, developed in partnership with the University of Oxford, consists of the gene for the spike protein of SARS-CoV-2 integrated into a harmless adenovirus.

"Vaccine efficacy was consistent across ethnicity and age". The trials also enrolled few elderly people, leaving open how well the vaccine protected that vulnerable group.

In an interview with ABC's Good Morning America, Fauci said that after the company put out its release Monday with the trial data and its efficacy conclusions, the DSMB "got concerned" the data was outdated and might be "misleading a bit". Still, the new results are "wonderful", she says.

After AstraZeneca announced advanced trial data on Monday that showed its COVID-19 vaccine to be 79 per cent effective, US federal health officials are now saying the results from the trial may have used "outdated information". AstraZeneca never applied for USA authorization of the vaccine, with company officials and Oxford scientists saying the agency gave them the strong impression the new trial's results were needed for that. During the trial, an unblinded statistical analysis group that is walled off from the company acts as an intermediary to handle data requests and many other interactions with the monitoring board.

On Friday, Ottawa and the US confirmed that the latter was finalizing a deal to "loan" 1.5 million AstraZeneca doses to Canada at the end of April. Given that the new vaccine results are good, that might look like overkill now. "But you can't know that before", Jha says.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.